Leerink analyst Faisal Khurshid upgraded Galapagos (GLPG) to Outperform from Market Perform with a price target of $40, up from $29. The firm has “renewed confidence” in the company’s plans to ease spending and pursue reasonable business development following the announcement that it would wind down its cell therapy business. In addition, Galapagos shares continue to trade at “deeply negative” enterprise value, the analyst tells investors in a research note. Leerink believes the company’s new management has proven capable of “making tough but needed decisions.” The firm sees the stock trading up towards Galapagos’ cash balance as the market gains confidence in management.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Galapagos upgraded to Outperform from Market Perform at Leerink
- Galapagos NV to Wind Down Cell Therapy Business Following Strategic Review
- Galapagos intends to wind down cell therapy business
- Galapagos Appoints Fred Blakeslee as General Counsel
- Galapagos Updates on Cell Therapy Business Strategic Review